Still the most comprehensive reference source on the development, production and therapeutic application of antibodies, this second edition is thoroughly updated and now has 30% more content. Volume I covers selection and engineering strategies for new antibodies, while the second volume look at novel therapeutic concepts and antibodies in clinical trial phases, as well as their potential. Volume III features detailed and specific information about each antibody currently approved for therapeutic purposes, including the clinical data. Beyond providing current knowledge, the authors discuss emerging technologies, future developments, and intellectual property issues, such that this handbook meets the needs of academic researchers, decision makers in industry and healthcare professionals in the clinic. INDICE: Technologies Foreword : Glassy A Greeting from the Editor: Dübel Introduction: Therapeutic Antibodies – From Past to Future Dübel Part I: Selecting and Shaping the Antibody Molecule Selection strategies I: Monoclonal Antibodies Moldenhauer Selection strategies II: Phage Antibody Display Hust Selection strategies III: Transgenic Mice Brüggemann Bioinformatic Tools for Antibody Engineering Martin Molecular Engineering I: Humanization Saldanha (X) Molecular Engineering II: Affinity Maturation Roskos Molecular Engineering III: Fc Engineering Valerius Part II: Preparing The Way into the Clinic Production and Downstream Processing Bergemann Pharmaceutical Formulation and Clinical Application Reich Immunogenicity of Antibody Therapeutics Schellekens Glycoanalytics Beck (new) Part III: Beyond IgG: Modified Antibodies Immunoscintigraphy and Radioimmunotherapy Dearling Bispecific Antibodies Kontermann Immunotoxins / Targeted RNases Rybak Part IV: Emerging Concepts Automation of Selection and Engineering Konthur Emerging Technologies for Antibody Selection Taussig Emerging Alternative Production Systems Jostock Non–Antibody Scaffolds Skerra Emerging Therapeutic Concepts I: ADEPT Sharma Emerging Therapeutic Concepts II: Nanotechnology Dimitrov Emerging Therapeutic Concepts III:Cell–bound antibodies Schirrmann Emerging Therapeutic Concepts IV:Anti–idiotypic Antibodies Fischer Recombinant Antibodies for target reserach Dübel (new) Therapeutics Part V: IP and regulatory issues Antibody engineering Patents Braunagel Quality standards of clinical studies Begent (new) Regulatory issues of approving antibody therapeutics Shapiro (FDA) Part VI: Ongoing Clinical Studies: Antibodies in Phase I/II/III: Cancer Therapy Deckert Antibodies in Phase I/II/III: Infectious Diseases N.N. (new) Antibodies in Phase I/II/III: Targeting TNF Neurath Part VII: Impact of Biosimilars of mAbs to innovative molecules N.N. IP expiration landscape and Biosimilar pathways N.N. High mAb Titer of Mammalian Cell Culture N.N. Advanced DSP for mAb Production N.N. Future mAb Manufacturing Facility: Flexibility and Feasible Sizes N.N. Part VIII: Approved Antibodies Serum Products Behrens (new) Adalimumab (Humira) Kupper Alemtuzumab (Mabcampath) Elter Bevacizumab (Avastin) Díaz–Rubio Cetuximab (Erbitux) Schleucher Efalizumab (Raptiva) Jahn/Schmitt Fanolesomab/Technetium99m (Neutrospec) Palestro Gemtuzumab Ozogamicin (Mylotarg) Gramatzki/Peipp Infliximab (Remicade) Antoni Muromonab (Orthoclone) Becker Natalizumab (Tysabri) Gold/Schimrigk Omalizumab (Xolair) Kroegel Palivizumab (Synagis) Schmidt AC Rituximab (Rituxan) Wenger Trastuzumab (Herceptin) Ellis Plus 8–10 articles on new technologies and additional antibodies approved after print of first edition. N.N. (new)
- ISBN: 978-3-527-32937-3
- Editorial: Wiley VCH
- Encuadernacion: Cartoné
- Páginas: 2000
- Fecha Publicación: 18/06/2014
- Nº Volúmenes: 1
- Idioma: Inglés